Hasten Biopharmaceutical Co Ltd announced the completion of the market authorization transfers for 11 pharmaceutical products across several key Asia-Pacific markets on June 16, marking a strategic leap forward in the domestic biopharmaceutical company's regional expansion.

The markets include China's Hong Kong Special Administrative Region, Malaysia, the Philippines, and Singapore, and the transferred products are mainly in the chronic disease field, particularly in the cardiovascular and diabetes segments.

The transfers were carried out by the company's affiliated entity, Hasten Biopharmaceutics (Asia) Co Ltd.

Hasten said such moves reinforce its commitments to building a robust, patient-centric commercial ecosystem in the Asia-Pacific market, and to bringing high-quality products and solutions to a wider range of patients.

"Together with our regional partners, we will accelerate the value transformation of high-quality products, broaden our global footprint, and be dedicated to co-creating a healthcare ecosystem that benefits patients worldwide," said Feng Honggang, chairman and CEO of Hasten.

Peggy Fung, vice-president and head of Asia-Pacific Commercial at Hasten, said: "We will continue to leverage our experience in commercializing mature products, together with multiple collaboration matrix that includes suppliers, distributors, and industry partners, to provide high-quality and accessible treatments to more patients across the Asia-Pacific region."

As an innovative biopharmaceutical company established in 2020, Hasten focuses on high-demand areas, including chronic diseases and acute care. In addition to carrying out multi-dimensional strategic cooperation with partners on the Chinese mainland, Hasten diversified its regional expansion by acquiring the commercial rights to a portfolio of branded products across eight countries and regions in the Asia-Pacific region last year, supported by the establishment of an experienced regional team to drive strategic growth.